Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients

14 maja 2026 zaktualizowane przez: Xin Yu, Sir Run Run Shaw Hospital

Efficacy of Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients With Colorectal Cancer: A Multicenter Randomized Controlled Trial Study Protocol

The goal of this clinical trial is to clarify the efficacy and safety of transcutaneous electrical acustimulation (TEA) in elderly patients with colorectal cancer, and to evaluate its clinical value in promoting postoperative intestinal function recovery and reducing the incidence of intestinal complications. The main questions it aims to answer are:

Can TEA promote the recovery of intestinal function in elderly patients with colon cancer after surgery? What medical problems might occur to the participants when using TEA? The researchers will compare TEA with the control group (non-acupoint sham stimulation) to see if TEA is effective in promoting the recovery of intestinal function after surgery.

Participants will:

Starting from the first day after the surgery, they received TEA or sham stimulation twice a day for a total of 3 days.

Record the time of the first defecation, defecation, and eating. Record their symptoms and adverse events.

Przegląd badań

Status

Jeszcze nie rekrutacja

Typ studiów

Interwencyjne

Zapisy (Szacowany)

190

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Zhejiang
      • Hangzhou, Zhejiang, Chiny

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Age ≥ 65 years old.
  • Elective minimally invasive (laparoscopic or robotic) resection of colorectal cancer.
  • American Society of Anesthesiologists classification (ASA) 1-4.
  • Able to understand the research process and the use of various assessment scales, and able to communicate effectively with the researchers.
  • The patient voluntarily participates in this study and signs the informed consent form.

Exclusion Criteria:

  • Previous history of abdominal gastrointestinal surgery.
  • Planned for palliative or emergency surgery.
  • Planned for open abdominal surgery or creation of a new stoma.
  • Transfer to ICU.
  • Diagnosed with severe heart, liver, kidney or mental system diseases.
  • Patients with implanted cardiac pacemakers.
  • Patients currently using or having used in the past month glucagon-like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
  • Planned to use epidural anesthesia or epidural analgesia.
  • Presence of local skin lesions, infection at the stimulation site, or obvious skin allergy or severe skin sensitivity to electrodes/adhesive materials.
  • Participated in other clinical studies within the past 3 months or received acupuncture treatment within the past month.
  • Other conditions that the investigator considers make the patient unsuitable for participation in this study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: TEA
The subjects in the TEA group were placed in the supine position and received transcutaneous electrical acupoint stimulation at the bilateral PC6 and bilateral ST36 . After confirming the location of the acupoints , special skin treatment was carried out. The stimulation parameters for PC6 were set as follows: 0.1 seconds of opening stimulation, 0.4 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 100 Hz, and amplitude ranging from 1 to 10 mA (based on the maximum level that the subject could tolerate). The stimulation parameters for ST36 were set as follows: 2 seconds of opening stimulation, 3 seconds of closing stimulation, pulse width of 0.5 ms, pulse frequency of 25 Hz, and amplitude ranging from 2 to 10 mA (based on the maximum level that the subject could tolerate).
Pozorny komparator: sham-TEA
Sham-TEA was the same except that non-acupoints were used to replace ST36 and PC6. The sham-acupoint for PC6 was located at about 15-20 cm away from PC6 (up to the elbow and outside of the coastal margin of the forearm not on any meridian) and the sham-point for ST36 was located at 10-15 cm down from and to the lateral side of ST36 not on any meridian

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Time to First Flatus
Ramy czasowe: Assessed up to 10 days after surgery
Defined as the period from the end of the surgery to the time of first flatus (hours).
Assessed up to 10 days after surgery

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Prolonged post operative ileus (PPOI)
Ramy czasowe: Assessed up to 72 hours after surgery
defined as no flatus for more than 72 hours
Assessed up to 72 hours after surgery
time to first defecation
Ramy czasowe: Assessed up to 10 days after surgery
Defined as the period from the end of the surgery to the time of first defecation (hours).
Assessed up to 10 days after surgery
time to first water intake
Ramy czasowe: Assessed up to 10 days after surgery
The time from the end of the surgery to the first water intake (hours)
Assessed up to 10 days after surgery
Time to tolerance of liquid diet
Ramy czasowe: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after the liquid diet. Record the time (in hours) from the end of the surgery to the first tolerance to the liquid diet.
Assessed up to 10 days after surgery
Time to tolerance of semi-liquid diet
Ramy czasowe: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after semi-liquid food. Record the time ( hours) from the end of the surgery to the first tolerance of semi-liquid food.
Assessed up to 10 days after surgery
Time to tolerance of solid food
Ramy czasowe: Assessed up to 10 days after surgery
"Tolerance" is defined as no significant nausea or vomiting (PONV ≤ 4 points) within 4 hours after solid food. Record the time (hours) from the end of the surgery to the first tolerance of solid food.
Assessed up to 10 days after surgery
Time to first ambulation
Ramy czasowe: Assessed up to 10 days after surgery
The time from the end of the surgery to the first ambulation (hours).
Assessed up to 10 days after surgery
Postoperative nausea
Ramy czasowe: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative nausea episodes
At 24, 48, and 72 hours after surgery
postoperative vomiting
Ramy czasowe: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative vomiting
At 24, 48, and 72 hours after surgery
postoperative abdominal distension
Ramy czasowe: At 24, 48, and 72 hours after surgery
The number and frequency of postoperative abdominal distension
At 24, 48, and 72 hours after surgery
Use of anti-emetic drugs after surgery
Ramy czasowe: At 24, 48, and 72 hours after surgery
Number of participants using antiemetic drugs
At 24, 48, and 72 hours after surgery
Severity of postoperative pain
Ramy czasowe: At 24, 48, and 72 hours after surgery
The assessment was conducted using a numerical rating scale (NRS). The scoring range was 0-10 (0 indicated no pain, while 10 indicated unbearable severe pain. Scores of 1-3 indicated mild pain that could be tolerated; 4-6 indicated pain that affected sleep but was still tolerable; 7-10 indicated severe pain that affected appetite and sleep).
At 24, 48, and 72 hours after surgery
Use of opioids drugs after surgery
Ramy czasowe: At 24, 48, and 72 hours after surgery
The total dosage of all opioid analgesics used within 24 hours, 48 hours, and 72 hours after surgery, converted into morphine equivalents.
At 24, 48, and 72 hours after surgery
TEA Security
Ramy czasowe: Assessed up to 3 days after surgery
assessing the adverse events related to the equipment (including numbness in the hands, pain, and skin allergies)
Assessed up to 3 days after surgery
Postoperative complications
Ramy czasowe: From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
The severity of complications was evaluated using the Clavien-Dindo classification system (grades I to V), with Clavien-Dindo grade ≥ III complications serving as the major surgical complications.
From the time the patient signs the informed consent form until the end of the study follow-up (30 days after surgery)
Total length of hospital stay
Ramy czasowe: Assessed up to 30 days after surgery
primary admission plus any readmission up to 30 days
Assessed up to 30 days after surgery
Unplanned readmission
Ramy czasowe: Assessed up to 30 days after surgery
Record the number of unplanned re-admissions within 30 days of hospital discharge
Assessed up to 30 days after surgery
Postoperative quality of recovery
Ramy czasowe: baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)
Assessed using the Quality of Recovery - 15 score (QoR-15) questionnaire preoperatively and daily. The total score ranges from 0 to 150 points. The higher the score, the better the post-anesthesia recovery quality.
baseline and postoperative day 1 to day 7 (or until discharge, whichever comes first)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 czerwca 2026

Zakończenie podstawowe (Szacowany)

31 grudnia 2028

Ukończenie studiów (Szacowany)

31 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

30 kwietnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

30 kwietnia 2026

Pierwszy wysłany (Rzeczywisty)

8 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

15 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

14 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak jelita grubego (CRC)

Badania kliniczne na TEA

Subskrybuj